Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the ...
Medscape21h
Intense Blood Pressure Lowering Benefit Confirmed in Diabetes
For patients with diabetes, a systolic target of 120 mm Hg led to a significant reduction in CV events in BPROADS, mirroring ...
Twisted Sifter on MSN22h
New Study Finds Promising Treatment For Type-1 Diabetes Using Patient’s Own Stem Cells
According to a new study, however, that may be changing. The team of researchers in China came up with a treatment that used ...
Challenges of managing diabetes in the elderly
Managing diabetes in older adults in India presents unique challenges due to age-related bodily changes and the prevalence of ...